Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 10/20 | 0.73 |
| ▸ | CDK1 | P06493 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.51 |
| ▸ | JAK2 | O60674 | 5/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27387131 | 0.85 | AXL (0.70) | AXLCDK1KDRJAK2JAK3 | |
| SCHEMBL12813273 | 0.85 | AXL (1.00) | AXLCDK1KDRJAK2JAK3 | |
| SCHEMBL12813489 | 0.83 | AXL (0.77) | AXLCDK1KDRJAK2 | |
| SCHEMBL12964726 | 0.82 | AXL (0.70) | AXLCDK1KDRJAK2JAK3 | |
| SCHEMBL12964739 | 0.81 | AXL (0.80) | AXLCDK1KDR | |
| SCHEMBL12813376 | 0.77 | AXL (1.00) | AXLCDK1KDR | |
| SCHEMBL12964729 | 0.77 | AXL (1.00) | AXL | |
| SCHEMBL21317668 | 0.76 | AXL (0.81) | AXLCDK1KDRJAK2JAK3 | |
| SCHEMBL25549984 | 0.76 | AXL (0.66) | AXLCDK1KDR | |
| SCHEMBL12964813 | 0.75 | AXL (0.73) | AXLCDK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | SUMITOMO PHARMA ONCOLOGY, INC. | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | AXL, TYRO3, MERTK | AXL 1/4885CDK1 248/4885KDR 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.